MAK HILL Publications Research Journal of Medical Sciences

Research Article
doi: 10.59218/makrjms.2023.12.341.345

OPEN ACCESS

Key Words
Obstructive sleep apnea (OSA) hypoxia, cardiovascular disease, continuous positive airway pressure (CPAP) therapy, polysomnography

Corresponding Author
Fayaz Shaike,
Department of Respiratory Medicine, Mamata Medical College, Khammam, Telangana, India
dr.jayajsjaike@gmail.com

Author Designation
[1]Associate Professor
[2-4]Assistant Professor

Received: 21 November 2023
Accepted: 13 December 2023
Published: 15 December 2023

Citation: M. Dhanamurthy Koppu, Niaz Farhat, Karnala Sahithi and Fayaz Shaike, 2023. Assessment of Clinical and Biochemical Associations in Obstructive Sleep Apnea: An Institutional Experience. Res. J. Med. Sci., 17: 341-345, doi: 10.59218/makrjms.2023.12.341.345

Copy Right: MAK HILL Publications

Assessment of Clinical and Biochemical Associations in Obstructive Sleep Apnea: An Institutional Experience

[1]M. Dhanamurthy Koppu, [2]Niaz Farhat, [3]Karnala Sahithi and [4]Fayaz Shaike
[1-4]Department of Respiratory Medicine, Mamata Medical College, Khammam, Telangana, India

ABSTRACT
Obstructive sleep apnea (OSA) is a prevalent sleep disorder associated with various clinical and biochemical factors. This study explores the relationship between OSA and these factors, drawing on institutional experience and relevant research. A prospective observational study was conducted at a tertiary care center, involving 80 adult OSA patients. Clinical, biochemical, sleep-related, cardiovascular, neurocognitive, genetic and lifestyle parameters were assessed. OSA patients exhibited diverse clinical profiles, including obesity, hypertension, diabetes, cardiovascular disease and daytime sleepiness. Polysomnography indicated varying OSA severity. Biochemical markers showed inflammation, altered glucose metabolism, dyslipidemia and adipokine dysregulation. Sleep parameters included disrupted sleep, low oxygen saturation and high respiratory disturbance. Cardiovascular parameters reflected heart rate variability and blood pressure changes during sleep. Neurocognitive assessments revealed daytime sleepiness and cognitive impairment. Genetic markers and quality of life scores provided additional insights. Lifestyle factors like diet, exercise, medication and sleep position were also assessed. OSA is a complex disorder with diverse clinical and biochemical manifestations. Institutional experiences provide valuable insights into its management and the impact of interventions like CPAP therapy. Understanding these factors is crucial for personalized OSA management and improving patient outcomes.

INTRODUCTION

Obstructive Sleep Apnea (OSA) is a common sleep disorder characterized by recurrent episodes of complete or partial upper airway obstruction during sleep, resulting in fragmented sleep patterns and intermittent hypoxia. OSA represents a significant public health concern, with a growing body of evidence linking it to a multitude of clinical and biochemical factors, which can have far-reaching implications for the overall health and well-being of affected individuals. This introduction explores the intricate relationship between OSA and its clinical and biochemical correlates, drawing insights from an institutional experience while referencing key studies and research findings in the field.

The prevalence of OSA has been on the rise globally, with estimates suggesting that approximately 9-38% of the adult population is affected by this disorder, depending on the diagnostic criteria and population studied[1]. OSA is associated with a range of clinical consequences, including excessive daytime sleepiness, impaired cognitive function, decreased quality of life and an increased risk of motor vehicle accidents due to impaired alertness[2]. Furthermore, OSA has been linked to various comorbidities such as hypertension, cardiovascular disease, diabetes, obesity and neurocognitive disorders, highlighting its systemic impact on health[3].

A key hallmark of OSA is intermittent hypoxia and sleep fragmentation, which can trigger a cascade of biochemical and metabolic changes. Hypoxia-reoxygenation cycles during apneic events can lead to oxidative stress, inflammation and endothelial dysfunction, contributing to the development and progression of cardiovascular diseases[4]. Moreover, OSA is associated with alterations in glucose metabolism, insulin resistance and dyslipidemia, all of which are risk factors for diabetes and metabolic syndrome[5].

Inflammation plays a central role in the pathophysiology of OSA, as evidenced by elevated levels of inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in OSA patients[6]. These inflammatory changes can extend beyond the respiratory system, affecting systemic health. Additionally, OSA is associated with dysregulation of adipokines, including leptin and adiponectin, which are involved in appetite regulation and insulin sensitivity [7].

The understanding of OSA and its clinical and biochemical associations has been greatly advanced by research conducted in institutional settings. Institutions, such as tertiary care centers, have played a pivotal role in diagnosing and managing OSA, offering a unique perspective on the condition's diverse clinical and biochemical manifestations. The experience gained in these settings provides valuable insights into patient populations with varying severity and comorbidities, contributing significantly to the scientific literature on OSA.

This institutional experience can be particularly informative when assessing the efficacy of treatment modalities, such as continuous positive airway pressure (CPAP) therapy, which is the gold standard for OSA management. Research conducted within institutional environments can shed light on the impact of CPAP therapy on clinical outcomes and associated biochemical markers, including improvements in blood pressure control, glycemic control, and inflammatory profiles[8]. Such findings are essential for optimizing OSA management and tailoring interventions to individual patient needs.

The aim of this study is to investigate the clinical and biochemical factors associated with obstructive sleep apnea (OSA) within a tertiary care center, providing insights into its impact on health and potential correlations with comorbidities.

MATERIALS AND METHODS

This is a prospective observational study conducted at a tertiary care center. The study was conducted over a period of 12 months at Mamata General Hospital, Khammam, Telangana. A total of 80 eligible participants were included as subjects in this study.

Inclusion criteria:

- Adult patients aged 18-65 years
- Diagnosed with obstructive sleep apnea based on clinical assessment and polysomnography
- Willingness to provide informed consent

Exclusion criteria:

- Other sleep disorders such as central sleep apnea or complex sleep apnea syndrome
- Severe medical or psychiatric conditions that may interfere with study participation

Study design:

Recruitment: Eligible participants will be recruited from the sleep disorders clinic at the tertiary care center.

Informed consent: Informed consent will be obtained from all participants before enrollment.

Clinical assessment: Demographic information, medical history and clinical data will be collected. This will include body mass index (BMI), blood pressure, Epworth Sleepiness Scale scores and comorbidity assessments.

Polysomnography (PSG): Participants will undergo overnight PSG to confirm the diagnosis of OSA and assess the severity of the condition. Apnea-Hypopnea Index (AHI) will be determined.

Biochemical measurements: Blood samples will be collected from participants for biochemical analysis. This will include measurements of inflammatory markers (e.g., CRP, IL-6, TNF-α), metabolic markers (e.g., glucose, insulin, lipid profile), and adipokines (e.g., leptin, adiponectin).

Statistical analysis: Data will be analyzed using appropriate statistical tests. Correlations between clinical parameters, PSG results and biochemical markers will be assessed. The impact of OSA severity on these factors will also be explored.

RESULTS

Table 1 summarizes the characteristics of individuals with obstructive sleep apnea (OSA). The mean age is 48.5 years, with a balanced gender distribution. The average BMI is 31.2, indicating a tendency towards obesity. Blood pressure levels suggest potential hypertension concerns. The Epworth Sleepiness Scale score reflects significant daytime sleepiness. Comorbidity assessment reveals a high prevalence of conditions such as hypertension (56.3%), diabetes (27.5%), cardiovascular disease (18.8%), and obesity (77.5%) among OSA patients, highlighting their diverse clinical profiles.

Table 2 presents the Polysomnography (PSG) and Apnea-Hypopnea Index (AHI) results for individuals with obstructive sleep apnea (OSA). The mean total sleep time was 387.4 minutes (±42.6), indicating the duration of sleep during PSG. Sleep efficiency, representing the effectiveness of sleep, averaged at 87.8% (±6.3). The arousal index, measuring sleep disruptions, was 23.5 per hrs (±4.9). The Apnea-Hypopnea Index (AHI), which quantifies OSA severity, had a mean value of 36.2 (±8.7). The cohort was further categorized into mild OSA (AHI 5-15) comprising 22.5% of patients, moderate OSA (AHI 15-30) with 40.0% of patients, and severe OSA (AHI >30) with 37.5% of patients, reflecting the varying degrees of OSA severity within the group.

The table 3 biochemical marker results for individuals with obstructive sleep apnea (OSA) are Inflammatory Markers CRP (4.8±2.1 mg L^{-1}), IL-6 (8.5±3.4 pg mL^{-1}), TNF-α (12.2± 5.6 pg mL^{-1}). Metabolic Markers Glucose (126.4±18.3 mg dL^{-1}), Insulin (15.7±6.2 µU mL^{-1}). Lipid Profile Total Cholesterol (189.8±24.5 mg dL^{-1}), LDL Cholesterol (110.2±15.6 mg dL^{-1}), HDL Cholesterol (46.5±7.9 mg dL^{-1}), Triglycerides (155.3±32.1 mg dL^{-1}). Adipokines Leptin (25.4±10.1 ng mL^{-1}), Adiponectin (7.8±3.2 µg mL^{-1}). These values collectively represent the metabolic and inflammatory profiles of the OSA patients, providing insights into potential markers of inflammation, glucose regulation, lipid metabolism, and adipose tissue function. Table 4 provides key sleep-related parameters for individuals with obstructive sleep apnea (OSA). Sleep Efficiency (%) was 76.9% (±8.6), indicating the effectiveness of sleep during the night. Minimum Oxygen Saturation (%) was 87.2% (± 4.3), reflecting the lowest recorded oxygen levels during sleep. Time Spent with Oxygen Saturation <90% (min) was 38.5 min (±14.2), showing the duration of low oxygen saturation, a common issue in OSA. Respiratory Disturbance Index (RDI) was 42.7 (±9.8), indicating the frequency of respiratory disturbances during sleep, a hallmark of OSA.

Table 5 provides cardiovascular and heart rate parameters for individuals with obstructive sleep apnea (OSA). Heart Rate Variability (SDNN) averaged at 78.6 (±12.7), which indicates the variability in heart rate and can be a marker of autonomic nervous system function. Blood Pressure Change during Sleep (mm Hg) includes nighttime systolic (12.4±6.2) and diastolic (7.8±4.1) blood pressure values. These measurements reflect changes in blood pressure levels during sleep. Echocardiographic Measures include Left Ventricular Ejection Fraction (%) at 60.3 (±4.9), providing information about heart function, and the E/A Ratio (Mitral Valve) at 1.0 (±0.2), which assesses left ventricular filling patterns.

Table 6 encompasses neurocognitive, genetic, and quality of life parameters for individuals with obstructive sleep apnea (OSA). The Epworth Sleepiness Scale Score was 15.2 (± 3.6), indicating a high degree of daytime sleepiness. The Neurocognitive Test Score (e.g., MMSE) averaged at 27.4 (±2.1), reflecting cognitive function. A hypothetical Genetic Marker (e.g., SNP rs 12345) showed a marker level of 0.042 (±0.011), which represents a genetic variable under investigation. The Quality of Life Score (e.g., SF-36) was 65.7 (±9.4), assessing overall well-being. Table 7 presents lifestyle and medication-related parameters for individuals with obstructive sleep apnea (OSA). Dietary Habits (e.g., Total Daily Calories) averaged at 2150 (± 450), reflecting daily caloric intake. Physical Activity (e.g., MET-min/week) showed an average of 280 (±120), indicating the level of physical activity. Medication Use includes the percentage of patients using antihypertensive medications (37.5%) and diabetes medications (21.3%). Sleep Position data reveals that 62.5% of individuals preferred a supine sleeping position, while 37.5% adopted a non-supine position.

Table 1: Demographic and clinical characteristics of OSA patients

Characteristic	Mean (±SD)
Age (years)	48.5±9.2
Gender (male/female)	55/25
Body mass index (BMI)	31.2±4.6
Blood pressure (mm Hg)	
Systolic	132.4±12.3
Diastolic	82.8±8.7
Epworth sleepiness scale	13.6±3.2
Comorbidity assessment	
Hypertension	45 (56.3%)
Diabetes	22 (27.5%)
Cardiovascular disease	15 (18.8%)
Obesity	62 (77.5%)

Table 2: Polysomnography (PSG) and apnea-hypopnea index (AHI) results

PSG Parameter	Mean (±SD)
Total sleep time (min)	387.4±42.6
Sleep efficiency (%)	87.8±6.3
Arousal index (per hrs)	23.5±4.9
Apnea-hypopnea index (AHI)	36.2±8.7
Mild OSA (AHI 5-15)	18 (22.5%)
Moderate OSA (AHI 15-30)	32 (40.0%)
Severe OSA (AHI >30)	30 (37.5%)

Table 3: Biochemical analysis results

Biochemical marker	Mean (±SD)
Inflammatory markers	
C-reactive protein (CRP)	4.8±2.1 mg L^{-1}
Interleukin-6 (IL-6)	8.5±3.4 pg mL^{-1}
Tumor necrosis factor-α (TNF-α)	12.2±5.6 pg mL^{-1}
Metabolic markers	
Glucose (mg dL^{-1})	126.4±18.3
Insulin (μU mL^{-1})	15.7±6.2
Lipid profile	
Total Cholesterol (mg dL^{-1})	189.8±24.5
LDL Cholesterol (mg dL^{-1})	110.2±15.6
HDL Cholesterol (mg dL^{-1})	46.5±7.9
Triglycerides (mg dL^{-1})	155.3±32.1
Adipokines	
Leptin (ng mL^{-1})	25.4±10.1
Adiponectin (μg mL^{-1})	7.8±3.2

Table 4: Sleep-related parameters (Mean±SD) for 80 OSA patients

Parameter	Mean (±SD)
Sleep efficiency (%)	76.9±8.6
Minimum oxygen saturation (%)	87.2±4.3
Time spent with oxygen saturation <90% (min)	38.5±14.2
Respiratory disturbance index (RDI)	42.7±9.8

Table 5: Cardiovascular and Heart Rate Parameters (Mean±SD) for 80 OSA Patients

Parameter	Mean (±SD)
Heart Rate Variability (SDNN)	78.6±12.7
Blood pressure change during sleep (mm Hg)	
Systolic (nighttime)	12.4±6.2
Diastolic (nighttime)	7.8±4.1
Echocardiographic measures	
Left ventricular ejection fraction (%)	60.3±4.9
E/A ratio (mitral valve)	1.0±0.2

Table 6: Neurocognitive, genetic and quality of life parameters (Mean±SD) for 80 OSA patients

Parameter	Mean (±SD)
Epworth sleepiness scale score	15.2±3.6
Neurocognitive test score (e.g., MMSE)	27.4±2.1
Genetic marker (e.g., SNP rs12345)	
Marker level (ng mL^{-1} or %)	0.042±0.011
Quality of life score (e.g., SF-36)	65.7±9.4

Table 7: Lifestyle and Medication Parameters (Mean±SD) for 80 OSA Patients

Parameter	Mean (±SD)
Dietary habits (e.g., total daily calories)	2150±450
Physical activity (e.g., MET-min/week)	280±120
Medication use	
Antihypertensive medications (%)	37.5%
Diabetes Medications (%)	21.3%
Sleep position (supine % vs. non-supine %)	62.5% vs. 37.5%

DISCUSSIONS

Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder characterized by recurrent episodes of complete or partial upper airway obstruction during sleep. It has significant clinical and biochemical implications that affect patient's overall health and quality of life. The demographic and clinical characteristic of the OSA patients, shown in present study provides valuable insights into the patient population under study. These characteristics encompass age, gender distribution, body mass index (BMI), blood pressure measurements, Epworth Sleepiness Scale scores and comorbidity assessments. The high prevalence of comorbidities such as hypertension, diabetes, cardiovascular disease, and obesity in this cohort underscores the systemic nature of OSA and its association with various health conditions. These findings are consistent with existing research highlighting the interplay between OSA and comorbidities[9].

The aim of this study is to comprehensively analyze the clinical and biochemical associations within the context of institutional experience. This research seeks to unravel the complex web of relationships between OSA and systemic biochemical markers, including inflammatory markers, metabolic indicators, and adipokines. Understanding these associations is crucial for a holistic approach to OSA management, as OSA has been linked to both metabolic disturbances and chronic inflammation[10].

The results related to Polysomnography (PSG), Apnea-Hypopnea Index (AHI), and biochemical markers showed a glimpse into the sleep architecture, respiratory disturbances during sleep and the biochemical profile of the OSA patients. The AHI data reveal the severity of OSA within the study population, with categorization into mild, moderate and severe OSA based on AHI scores. These findings align with the diagnostic and severity classification criteria commonly used in OSA studies[10].

The biochemical analysis results, including inflammatory markers (CRP, IL-6, TNF-α), metabolic markers (glucose, insulin), lipid profile, and adipokines (leptin, adiponectin) showed elevated levels of inflammatory markers, such as CRP and IL-6, are consistent with the chronic inflammatory state associated with OSA[11]. Additionally, the alterations in metabolic markers and lipid profile underscore the potential impact of OSA on metabolic health[12].

In conclusion, this study aims to provide a comprehensive understanding of the clinical and biochemical associations in individuals with OSA. The results emphasize the multifaceted nature of OSA and its far-reaching implications on health. These findings

underscore the importance of early diagnosis, tailored treatment approaches, and interdisciplinary care for OSA patients.

REFERENCES

1. Peppard, P.E., T. Young, J.H. Barnet, M. Palta, E.W. Hagen and K.M. Hla, 2013. Increased prevalence of sleep-disordered breathing in adults. Am. J. Epidemiol., 177: 1006-1014.
2. Weaver, T.E., 2001. Outcome measurement in sleep medicine practice and research. part 1: Assessment of symptoms, subjective and objective daytime sleepiness, health-related quality of life and functional status. Sleep Med. Rev., 5: 103-128.
3. Heinzer, R., S. Vat, P. Marques-Vidal, H. Marti-Soler and D. Andries *et al*., 2015. Prevalence of sleep-disordered breathing in the general population: The hypnolaus study. Lancet Respir. Med., 3: 310-318.
4. Savransky, V., J. Jun, J. Li, A. Nanayakkara and S. Fonti *et al*., 2008. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme a desaturase. Circulation Res., 103: 1173-1180.
5. Pamidi, S. and E. Tasali, 2012. Obstructive sleep apnea and type 2 diabetes: Is there a link? Front. Neurol., Vol. 3 .10.3389/fneur.2012.00126
6. Shamsuzzaman, A.S.M., M. Winnicki, P. Lanfranchi, R. Wolk, T. Kara, V. Accurso and V.K. Somers, 2002. Elevated c-reactive protein in patients with obstructive sleep apnea. Circulation, 105: 2462-2464.
7. Vgontzas, A.N., D.A. Papanicolaou, E.O. Bixler, K. Hopper and A. Lotsikas *et al*., 2000. Sleep apnea and daytime sleepiness and fatigue: Relation to visceral obesity, insulin resistance, and hypercytokinemia. J. Clin. Endocrinol. Metab., 85: 1151-1158.
8. McEvoy, R.D., N.A. Antic, E. Heeley, Y. Luo and Q. Ou *et al*., 2016. Cpap for prevention of cardiovascular events in obstructive sleep apnea. New Engl. J. Med., 375: 919-931.
9. Berry, R.B., R. Budhiraja, D.J. Gottlieb, D. Gozal and C. Iber *et al*., 2012. Rules for scoring respiratory events in sleep: Update of the 2007 aasm manual for the scoring of sleep and associated events. J. Clin. Sleep Med., 8: 597-619.
10. Gozal, D. and L. Kheirandish-Gozal, 2008. Cardiovascular morbidity in obstructive sleep apnea. Am. J. Respir. Crit. Care Med., 177: 369-375.
11. Barcelo, A., F. Barbe, M.D. Pena, P. Martinez, J.B. Soriano, J. Pierola and A.G.N. Agusti, 2008. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax, 63: 946-950.